Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with locally advanced laryngeal carcinoma

Eur Arch Otorhinolaryngol. 2005 Feb;262(2):93-8. doi: 10.1007/s00405-004-0749-5. Epub 2004 Feb 18.


An alternative treatment in patients with advanced laryngeal carcinoma who are candidates for total laryngectomy is induction chemotherapy and radical radiotherapy in an organ preservation approach. We conducted a study to evaluate results of this treatment in patients with locally advanced laryngeal carcinoma, candidates for total laryngectomy, who were treated at a single institution between 1985 and 1997. During the study period, 224 began treatment with induction chemotherapy. Induction chemotherapy consisted of three cycles of cisplatin and 5-fluoruracil in the majority of cases. Four patients died as a consequence of complications associated with chemotherapy treatment. Subsequent treatment consisted of total laryngectomy in 79 patients and radical radiotherapy in 141. After radical radiotherapy, local control for patients who achieved a complete response after induction chemotherapy was 74%, significantly better than 57% in patients with a non-complete response (P=0.04). Considering the initial group of 224 patients, the frequency of organ preservation was 39%. Considering only the patients treated with induction chemotherapy and radiotherapy, the organ preservation frequency was 62%. In a multivariate study, only the response after induction chemotherapy was significantly related to organ preservation.

Publication types

  • Clinical Trial

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Chi-Square Distribution
  • Cisplatin / administration & dosage
  • Clinical Protocols
  • Combined Modality Therapy
  • Fluorouracil / administration & dosage
  • Humans
  • Laryngeal Neoplasms / therapy*
  • Laryngectomy
  • Logistic Models
  • Neck Dissection
  • Radiotherapy, High-Energy
  • Remission Induction / methods
  • Survival Analysis
  • Treatment Outcome


  • Antineoplastic Agents
  • Cisplatin
  • Fluorouracil